Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers

Dani Cohen, Shai Ashkenazi, Manfred S. Green, Miri Yavzori, Nadav Orr, Raphael Slepon, Yehuda Lerman, Guy Robin, Ruhama Ambar, Colin Block, David N. Taylor, Thomas L. Hale, Jerald C. Sadoff, Michael Wiener

Research output: Contribution to journalArticlepeer-review


A double-blind placebo-controlled study was carried out on the safety and immunogenicity of the oral Shigella flexneri (EcSf2a-2) vaccine among Israeli soldiers. Sixty volunteers received the vaccine and 59 received placebo. Fifty-three were given the full vaccine regimen (four doses). Doses ranged between 4.1 × 108 and 1.1 × 109 c.f.u. Visits to the unit clinic for mild gastrointestinal symptoms were common after the first dose in vaccinees (13%) as compared with placebo recipients (5%), but the difference was not significant, p = 0.12. Similarly, there was no difference between the groups for either gastrointestinal or non-gastrointestinal complaints reported by questionnaire. The vaccine strain was excreted by 69% and 67% of the vaccinees one day after receiving the second and the fourth doses, respectively. As judged by antibiotic susceptibility, phage typing and restriction fragment length polymorphism (RFLP), the vaccine strain emerged as genetically stable after replication in human gut and shedding. There was neither bacteriological nor serological evidence of transmission of the vaccine from vaccinees to placebo recipients. Eighteen of 26 (69.2%) and 11 of 30 (36.7%) vaccinees had significant IgA secreting cell responses 7 and 21 days after the first dose, respectively. Significant IgA or IgG serum antibody response to S. flexneri 2a LPS was detected in 30% of the vaccinees. These results support further evaluation of EcSf2a-2 vaccine protective efficacy in field studies.

Original languageEnglish
Pages (from-to)1436-1442
Number of pages7
Issue number15
StatePublished - 1994
Externally publishedYes

Bibliographical note

Funding Information:
This study was supported by Grant No. DAMD17-88-z-8010 from US Army Medical Research and Development Command, Fort Detrick, Frederick, MD. The authors are grateful to Dr I. Sechter for phage-typing of the vaccine strains and thank Mrs Rachel Heller-Mendelzis for very helpful technical assistance.


  • EcSf2a-2 hybrid vaccine
  • Oral immunization
  • Shigella flexneri

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology (all)
  • Veterinary (all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers'. Together they form a unique fingerprint.

Cite this